Phase III, randomised, multicenter study to assess the efficacy and safety of HuM195 (recombinant humanized anti-CD33 monoclonal antibody) in combination with standardized chemotherapy compared to standardized chemotherapy alone in the treatment of patients with refractory or first-relapsed acute myelogenous leukemia (AML).
Phase of Trial: Phase III
Latest Information Update: 23 Feb 2010
At a glance
- Drugs Cytarabine; Etoposide; Lintuzumab; Mitoxantrone
- Indications Acute myeloid leukaemia
- Focus Registrational; Therapeutic Use
- 11 Sep 2005 New trial record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History